Keywords: xenical, reduces, cv, disease, risk, hoffmann-la, roche
Xenical "reduces CV disease risk"
Article | 03 September 1999
- Hoffmann-La Roche's antiobesity drug Xenical (orlistat), incombination with a low-calorie diet, can significantly reduce the risk of cardiovascular disease in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
